Progress in the treatment of Pneumocystis pneumonia

Tong-Zeng Li
{"title":"Progress in the treatment of Pneumocystis pneumonia","authors":"Tong-Zeng Li","doi":"10.3760/CMA.J.ISSN.1673-436X.2020.02.014","DOIUrl":null,"url":null,"abstract":"Pneumocystis pneumonia (PCP) is a pulmonary disease that occurs frequently in immunocompromised and acquired human immunodeficiency virus infected patients.Severe patients can be life-threatening.Trimethoprim-sulfamethoxazole is the first choice for first-line treatment, but it has potential drug resistance.Most mild patients have good prognosis after using compound sulfamethoxazole and active treatment of primary diseases.However, for severe patients, due to lack of specific diagnostic methods in the early stage, the course of disease progresses rapidly, and glucocorticoid therapy can be combined to reduce the mortality of PCP.This article reviews the progress of treatment of PCP. \n \n \nKey words: \nPneumonia; Homones; Sulfamethoxazole; Spores","PeriodicalId":10004,"journal":{"name":"Chinese Journal of Asthma","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chinese Journal of Asthma","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1673-436X.2020.02.014","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Pneumocystis pneumonia (PCP) is a pulmonary disease that occurs frequently in immunocompromised and acquired human immunodeficiency virus infected patients.Severe patients can be life-threatening.Trimethoprim-sulfamethoxazole is the first choice for first-line treatment, but it has potential drug resistance.Most mild patients have good prognosis after using compound sulfamethoxazole and active treatment of primary diseases.However, for severe patients, due to lack of specific diagnostic methods in the early stage, the course of disease progresses rapidly, and glucocorticoid therapy can be combined to reduce the mortality of PCP.This article reviews the progress of treatment of PCP. Key words: Pneumonia; Homones; Sulfamethoxazole; Spores
肺囊虫性肺炎的治疗进展
肺囊虫性肺炎(PCP)是一种常见于免疫功能低下和获得性人类免疫缺陷病毒感染患者的肺部疾病。严重的病人可能危及生命。甲氧苄啶-磺胺甲恶唑是一线治疗的首选药物,但有潜在的耐药性。多数轻症患者在应用复方磺胺甲恶唑并积极治疗原发疾病后预后良好。但对于重症患者,由于早期缺乏特异性的诊断方法,病程进展迅速,可联合糖皮质激素治疗,降低PCP的死亡率。本文就PCP的治疗进展作一综述。关键词:肺炎;性激素;磺胺甲恶唑;孢子
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信